Read by QxMD icon Read

Therapeutic Advances in Cardiovascular Disease

Bart Hiemstra, Remco Bergman, Anthony R Absalom, Joukje van der Naalt, Pim van der Harst, Ronald de Vos, Wybe Nieuwland, Maarten W Nijsten, Iwan C C van der Horst
BACKGROUND: Over the past decade, prehospital and in-hospital treatment for out-of-hospital cardiac arrest (OHCA) has improved considerably. There are sparse data on the long-term outcome, especially in elderly patients. We studied whether elderly patients benefit to the same extent compared with younger patients and at long-term follow up as compared with the general population. METHODS: Between 2001 and 2010, data from all patients presented to our hospital after OHCA were recorded...
September 20, 2018: Therapeutic Advances in Cardiovascular Disease
Kaveh Eghbalzadeh, Anton Sabashnikov, Carolyn Weber, Mohamed Zeriouh, Ilija Djordjevic, Julia Merkle, Olga Shostak, Sergey Saenko, Payman Majd, Oliver Liakopoulos, Parwis B Rahmanian, Navid Madershahian, Yeong-Hoon Choi, Ferdinand Kuhn-Régnier, Jens Wippermann, Thorsten Wahlers
BACKGROUND: The aim of the present study was to determine whether raised preoperative serum creatinine affected the long-term outcome in patients undergoing surgical aortic repair for Stanford A acute aortic dissection (AAD). METHODS: A total of 240 patients diagnosed with Stanford A AAD underwent surgical repair from January 2006 to April 2015. A propensity score matching was applied, resulting in 73 pairs consisting of one group with normal and one group with preoperative elevated creatinine levels...
September 19, 2018: Therapeutic Advances in Cardiovascular Disease
Eduardo M Vilela, Catarina Ruivo, Claudio E Guerreiro, Marisa P Silva, Ricardo Ladeiras-Lopes, Daniel Caeiro, Gustavo P Morais, João Primo, Pedro Braga, Nuno Ferreira, José Pedro L Nunes, Vasco Gama Ribeiro
BACKGROUND: Pericardial effusion (PE) can develop in several pathological scenarios, and is often initially evaluated by means of echocardiography. Computed tomography (CT) has been used as an aid in the management of patients presenting with PE, in selected cases. The role of CT-guided pericardiocentesis in contemporary practice, however, remains not fully ascertained. We aimed at presenting a systematic review concerning the state-of-the-art of this technique. METHODS: A systematic review of published data on the use of CT for guiding pericardiocentesis was carried out (search performed on PubMed, ISI Web of Knowledge and Scopus databases)...
August 15, 2018: Therapeutic Advances in Cardiovascular Disease
(no author information available yet)
No abstract text is available yet for this article.
July 1, 2018: Therapeutic Advances in Cardiovascular Disease
José López-Menéndez, Javier Miguelena, Carlos Morales, Francisco Callejo, Jacobo Silva
BACKGROUND: We analyzed the adequacy of the myocardial protection achieved with a single dose of retrograde crystalloid Celsior®, compared with an accepted standard (microplegia), in on-pump coronary artery bypass grafting surgery (CABG). METHODS: This was a retrospective comparative clinical study conducted in a single institution that included all the patients operated on who had elective isolated on-pump CABG, from March 2006 to June 2014. We evaluated maximum postoperative troponin T (TnT) as a marker of myocardial damage, adjusted for possible confounders using propensity score matching...
October 2018: Therapeutic Advances in Cardiovascular Disease
Yuji Kanaoka, Takao Ohki, Koji Kurosawa, Koji Maeda, Kota Shukuzawa, Masayuki Hara, Takeshi Baba, Reo Takizawa, Hiromasa Tachihara
BACKGROUND: The aim of this study was to evaluate endovascular treatment for enlarged Stanford type B chronic aneurysmal aortic dissection (CAAD). The conventional treatment for CAAD is open repair; however, the operative mortality is high in extensive prosthetic graft replacements. METHODS: A retrospective single-center study was conducted on 74 consecutive patients who underwent endovascular treatment for CAAD in the past 8.5 years. In the partial exclusion (PE) group, entry sites in close proximity to the maximum diameter of CAAD were closed using a stent graft and reentry sites were left without closure...
October 2018: Therapeutic Advances in Cardiovascular Disease
Zachary A Stacy, Sara K Richter
BACKGROUND: To review data from the pivotal phase III trials evaluating the efficacy and safety of direct oral anticoagulants (DOACs) versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF), and to summarize the major findings with regards to patient subgroups that are at an increased risk for stroke or bleeding. METHODS: A PubMed literature search (January 2009 to January 2017) was performed using the terms 'dabigatran', 'rivaroxaban', 'apixaban', 'edoxaban', 'atrial fibrillation', 'RE-LY', 'ROCKET AF', 'ARISTOTLE', and 'ENGAGE AF-TIMI 48'...
September 2018: Therapeutic Advances in Cardiovascular Disease
Roman Deev, Igor Plaksa, Ilia Bozo, Nina Mzhavanadze, Igor Suchkov, Yuriy Chervyakov, Ilia Staroverov, Roman Kalinin, Artur Isaev
BACKGROUND: The effective treatment of chronic lower limb ischemia is one of the most challenging issues confronting vascular surgeons. Current pharmacological therapies play an auxiliary role and cannot prevent disease progression, and new treatment methods are needed. In 2011, a plasmid VEGF65-gene therapy drug was approved in Russia for the treatment of chronic lower limb ischemia ( identifier: NCT03068585). The objective of this follow-up study was to evaluate the long-term safety and efficacy of gene therapy in patients with limb ischemia of atherosclerotic genesis...
September 2018: Therapeutic Advances in Cardiovascular Disease
Srikanth Yandrapalli, Mohammed Hasan Khan, Yogita Rochlani, Wilbert S Aronow
Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world. Mortality from CV disease had plateaued in the recent years raising concerning alarms about the sustained efficacy of available preventive and treatment options. Heart failure (HF) is among the major contributors to the CV-related health care burden, a persisting concern despite the use of clinically proven guideline-directed therapies. A requirement for more efficient medical therapies coupled with recent advances in bio-innovation led to the creation of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), which demonstrated substantial CV benefit when compared with the standard of care, enalapril, in patients with HF and reduced ejection fraction...
August 2018: Therapeutic Advances in Cardiovascular Disease
Katie B Tellor, Steffany N Nguyen, Amanda C Bultas, Anastasia L Armbruster, Nicholas A Greenwald, Abigail M Yancey
BACKGROUND: Despite well established empiric dose adjustments for drug and disease-state interactions, the impact of body mass index (BM) on warfarin remains unclear. The objective of this study is to evaluate warfarin requirements in hospitalized patients, stratified by BMI. METHODS: This retrospective review included two cohorts of patients: cohort A (patients admitted with a therapeutic international normalized ratio (INR)) and cohort B (newly initiated on warfarin during hospitalization)...
August 2018: Therapeutic Advances in Cardiovascular Disease
Elena Conroy
No abstract text is available yet for this article.
August 2018: Therapeutic Advances in Cardiovascular Disease
Christos Zivlas, Filippos Triposkiadis, Stelios Psarras, Gregory Giamouzis, Ioannis Skoularigis, Stavros Chryssanthopoulos, Alkistis Kapelouzou, Steve Ramcharitar, Edward Barnes, Evangelos Papasteriadis, Dennis Cokkinos
No abstract text is available yet for this article.
August 2018: Therapeutic Advances in Cardiovascular Disease
Johann Auer, Robert Berent
Atherosclerotic cardiovascular diseases (ASCVDs) are associated with a substantial mortality, physical morbidity, and mental disability. Elevated plasma low-density lipoprotein cholesterol (LDL-C) levels play a major role in the pathophysiology of ASCVDs. Statins have been shown to reduce ASCVD risk and associated events and are recommended as first-line therapy for treatment of hypercholesterolemia by current international guidelines. The key issue is to attain guideline-recommended LDL-C levels (below 70 mg/dl) for patients at very high cardiovascular risk...
July 2018: Therapeutic Advances in Cardiovascular Disease
Virna Margarita Martín Giménez, Sandra Edith Noriega, Diego Enrique Kassuha, Lucía Beatriz Fuentes, Walter Manucha
Cardiovascular disease is currently not adequately managed and has become one of the main causes of morbidity and mortality worldwide. Current therapies are inadequate in terms of preventing its progression. There are several limitations, such as poor oral bioavailability, side effects, low adherence to treatment, and high dosage frequency of formulations due to the short half-life of the active ingredients used, among others. This review aims to highlight the most relevant aspects of the relationship between the cardiovascular system and the endocannabinoid system, with special attention to the possible translational effect of the use of anandamide in cardiovascular health...
July 2018: Therapeutic Advances in Cardiovascular Disease
Gianluca Rigatelli, Marco Zuin, Fabio Dell'Avvocata, Thach Nguyen
Background The aim of this study was to evaluate the rheolytic effects of stenting a mid-shaft/distal left main coronary artery (LMCA) lesion with and without ostial coverage. Stenting of the LMCA has emerged as a valid alternative in place of traditional coronary bypass graft surgery. However, in case of mid-shaft/distal lesion, there is no consensus regarding the extension of the strut coverage up to the ostium or to stent only the culprit lesion. Methods We reconstructed a left main-left descending coronary artery (LM-LCA)-left circumflex (LCX) bifurcation after analysing 100 consecutive patients (mean age 71...
June 2018: Therapeutic Advances in Cardiovascular Disease
Patricio López-Jaramillo, Silvia González-Gómez, Diego Zarate-Bernal, Andrés Serrano, Leonor Atuesta, Christian Clausen, Claudia Castro-Valencia, Paul Camacho-Lopez, Johanna Otero
The simplification of fixed dose medications by using a single 'polypill' is an attractive strategy to improve adherence to medications which has shown benefit to cardiovascular risk factor control and cardiovascular disease prevention or delay in the progression of these diseases. We review the evidence obtained from a series of clinical trials demonstrating an improvement in adherence to the polypill compared to the use of each compound separately, and found similar or better control of the classical cardiovascular risk factors and a similar safety profile...
June 2018: Therapeutic Advances in Cardiovascular Disease
Jaroslaw Ucieklak, Robert Michał Proczka
A rare case of clinical complication following a percutaneous coronary intervention is presented. A femoral vascular access was chosen to treat a coronary lesion with a stent implantation. This femoral vascular access, however, resulted in a pyogenic infection of the ipsilateral hip joint that was not properly diagnosed for an extended post-interventional period. The hip joint completely deteriorated before its underlying cause was identified. This case report illustrates the importance of recognizing potential endovascular complications independently of their frequency...
May 2018: Therapeutic Advances in Cardiovascular Disease
Axel Haine, Alan G Haynes, Andreas Limacher, Tim Sebastian, Wuttichai Saengprakai, Torsten Fuss, Iris Baumgartner
BACKGROUND: Patency of the pedal-plantar arch limits risk of amputation in peripheral artery disease (PAD). We examined patients without chronic kidney disease (CKD)/diabetes mellits (DM) [PAD-control], those with DM without CKD, and those with CKD without DM. METHOD: Uni- and multivariate logistic regression was used to assess association of CKD with loss of patency of the pedal-plantar arch and presence of tibial or peroneal vessel occlusion. Multivariate models adjusted for age, sex, hypertension, hyperlipidemia and smoking...
May 2018: Therapeutic Advances in Cardiovascular Disease
Daniel Brancheau, Sinan Sarsam, Mahmoud Assaad, Marcel Zughaib
BACKGROUND: Patients who are candidates to receive an Angioseal® (St. Jude Medical) device for arteriotomy closure are allowed to ambulate 20 min after the deployment of the device. More frequently, however, patients are kept on bed rest for several hours following Angioseal® deployment. The purpose of this study was to prospectively assess patients when ambulating 20 min after Angioseal® deployment instead of prolonged best rest of 2-3 h. METHODS: Patients undergoing angiography from the common femoral artery approach were included in the study if they received a 6 Fr Angioseal® closure device...
May 2018: Therapeutic Advances in Cardiovascular Disease
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"